Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | MMP13 | P45452 | 2/20 | 0.50 |
| ▸ | STAMBP | O95630 | 1/20 | 0.49 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HPGDS | O60760 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6253500 | 0.83 | MAPT (0.56) | HPGDKDM4EALDH1A1MAPTMMP13 | |
| SCHEMBL6510453 | 0.81 | ALDH1A1 (0.54) | HPGDKDM4EALDH1A1MAPTMMP13 | |
| SCHEMBL17434334 | 0.78 | HPGD (0.57) | HPGDKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL6518748 | 0.78 | MMP13 (0.54) | HPGDKDM4EALDH1A1MAPTMMP13 | |
| SCHEMBL6509576 | 0.78 | MAPT (0.56) | ALDH1A1MAPTMMP13MEN1KMT2A | |
| SCHEMBL6464565 | 0.78 | MMP13 (0.60) | ALDH1A1MAPTMMP13KDM1AHDAC1 | |
| SCHEMBL7031009 | 0.76 | MAPT (0.63) | HPGDKDM4EALDH1A1MAPTHDAC1 | |
| SCHEMBL6258768 | 0.76 | MMP13 (0.50) | ALDH1A1MAPTMMP13STAMBPCOPS5 | |
| SCHEMBL5215056 | 0.73 | KDM1A (0.72) | HPGDALDH1A1MAPTMMP13STAMBP | |
| SCHEMBL7101052 | 0.73 | MMP13 (0.61) | HPGDALDH1A1MAPTMMP13MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2005-01-06 | — | — | US | disclosed |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | MMP13, MMP9, MMP3 | HPGD 228/4885KDM4E 1784/4885ALDH1A1 1357/4885 |
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | MMP13, MMP12, MMP25 | HPGD 397/4885KDM4E 2484/4885ALDH1A1 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.